Cargando…

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma

PURPOSE: Anlotinib, a newly developed oral small-molecule receptor tyrosine kinase inhibitor (TKI), has been shown to have encouraging activity against sarcoma. The purpose of this study was to retrospectively evaluate the safety and clinical efficacy of chemotherapy combined with anlotinib plus anl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hai-ying, Chu, Jun-feng, Zhang, Peng, Wang, Jia-qiang, Yan, Zheng, Yao, Shu-na, Yao, Zhi-hua, Liu, Yan-yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038775/
https://www.ncbi.nlm.nih.gov/pubmed/32110053
http://dx.doi.org/10.2147/OTT.S235349
_version_ 1783500711944781824
author Wang, Hai-ying
Chu, Jun-feng
Zhang, Peng
Wang, Jia-qiang
Yan, Zheng
Yao, Shu-na
Yao, Zhi-hua
Liu, Yan-yan
author_facet Wang, Hai-ying
Chu, Jun-feng
Zhang, Peng
Wang, Jia-qiang
Yan, Zheng
Yao, Shu-na
Yao, Zhi-hua
Liu, Yan-yan
author_sort Wang, Hai-ying
collection PubMed
description PURPOSE: Anlotinib, a newly developed oral small-molecule receptor tyrosine kinase inhibitor (TKI), has been shown to have encouraging activity against sarcoma. The purpose of this study was to retrospectively evaluate the safety and clinical efficacy of chemotherapy combined with anlotinib plus anlotinib maintenance in advanced/metastatic soft tissue sarcoma (STS) patients in a real-world setting in China. PATIENTS AND METHODS: We retrospectively collected the medical data of thirty-two patients with advanced/metastatic STS who received chemotherapy combined with anlotinib plus anlotinib maintenance therapy. The objective response rate (ORR) and disease control rate (DCR) were calculated according to the RECIST 1.1 criteria. The progression-free rates (PFRs) at three and six months, the progression-free survival (PFS) time, and adverse events were recorded. RESULTS: On the basis of investigator assessments, two patients (6%) achieved CR (complete response) and nine patients (28%) achieved PR (partial response), with an ORR of 34%. Eleven patients (34%) achieved SD (stable disease), and ten patients (31%) achieved PD (progression disease), with a DCR of 69%. The progression-free rates (PFRs) at three and six months were 81% and 69%, respectively. The median PFS time was 8.2 months. The hematologic and non-hematologic toxicities were manageable. The most common grade 3 and 4 adverse events were febrile neutropenia (9%), leukopenia (19%), thrombocytopenia (3%), anemia (6%), anorexia (6%), vomiting (3%), and hypertension (6%). The combination therapy was generally well tolerated. CONCLUSION: Our study suggests that chemotherapy combined with anlotinib plus anlotinib maintenance therapy had good efficacy and resulted in more favorable survival with good tolerance among patients with advanced/metastatic STS.
format Online
Article
Text
id pubmed-7038775
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-70387752020-02-27 Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma Wang, Hai-ying Chu, Jun-feng Zhang, Peng Wang, Jia-qiang Yan, Zheng Yao, Shu-na Yao, Zhi-hua Liu, Yan-yan Onco Targets Ther Original Research PURPOSE: Anlotinib, a newly developed oral small-molecule receptor tyrosine kinase inhibitor (TKI), has been shown to have encouraging activity against sarcoma. The purpose of this study was to retrospectively evaluate the safety and clinical efficacy of chemotherapy combined with anlotinib plus anlotinib maintenance in advanced/metastatic soft tissue sarcoma (STS) patients in a real-world setting in China. PATIENTS AND METHODS: We retrospectively collected the medical data of thirty-two patients with advanced/metastatic STS who received chemotherapy combined with anlotinib plus anlotinib maintenance therapy. The objective response rate (ORR) and disease control rate (DCR) were calculated according to the RECIST 1.1 criteria. The progression-free rates (PFRs) at three and six months, the progression-free survival (PFS) time, and adverse events were recorded. RESULTS: On the basis of investigator assessments, two patients (6%) achieved CR (complete response) and nine patients (28%) achieved PR (partial response), with an ORR of 34%. Eleven patients (34%) achieved SD (stable disease), and ten patients (31%) achieved PD (progression disease), with a DCR of 69%. The progression-free rates (PFRs) at three and six months were 81% and 69%, respectively. The median PFS time was 8.2 months. The hematologic and non-hematologic toxicities were manageable. The most common grade 3 and 4 adverse events were febrile neutropenia (9%), leukopenia (19%), thrombocytopenia (3%), anemia (6%), anorexia (6%), vomiting (3%), and hypertension (6%). The combination therapy was generally well tolerated. CONCLUSION: Our study suggests that chemotherapy combined with anlotinib plus anlotinib maintenance therapy had good efficacy and resulted in more favorable survival with good tolerance among patients with advanced/metastatic STS. Dove 2020-02-19 /pmc/articles/PMC7038775/ /pubmed/32110053 http://dx.doi.org/10.2147/OTT.S235349 Text en © 2020 Wang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wang, Hai-ying
Chu, Jun-feng
Zhang, Peng
Wang, Jia-qiang
Yan, Zheng
Yao, Shu-na
Yao, Zhi-hua
Liu, Yan-yan
Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
title Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
title_full Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
title_fullStr Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
title_full_unstemmed Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
title_short Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
title_sort safety and efficacy of chemotherapy combined with anlotinib plus anlotinib maintenance in chinese patients with advanced/metastatic soft tissue sarcoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038775/
https://www.ncbi.nlm.nih.gov/pubmed/32110053
http://dx.doi.org/10.2147/OTT.S235349
work_keys_str_mv AT wanghaiying safetyandefficacyofchemotherapycombinedwithanlotinibplusanlotinibmaintenanceinchinesepatientswithadvancedmetastaticsofttissuesarcoma
AT chujunfeng safetyandefficacyofchemotherapycombinedwithanlotinibplusanlotinibmaintenanceinchinesepatientswithadvancedmetastaticsofttissuesarcoma
AT zhangpeng safetyandefficacyofchemotherapycombinedwithanlotinibplusanlotinibmaintenanceinchinesepatientswithadvancedmetastaticsofttissuesarcoma
AT wangjiaqiang safetyandefficacyofchemotherapycombinedwithanlotinibplusanlotinibmaintenanceinchinesepatientswithadvancedmetastaticsofttissuesarcoma
AT yanzheng safetyandefficacyofchemotherapycombinedwithanlotinibplusanlotinibmaintenanceinchinesepatientswithadvancedmetastaticsofttissuesarcoma
AT yaoshuna safetyandefficacyofchemotherapycombinedwithanlotinibplusanlotinibmaintenanceinchinesepatientswithadvancedmetastaticsofttissuesarcoma
AT yaozhihua safetyandefficacyofchemotherapycombinedwithanlotinibplusanlotinibmaintenanceinchinesepatientswithadvancedmetastaticsofttissuesarcoma
AT liuyanyan safetyandefficacyofchemotherapycombinedwithanlotinibplusanlotinibmaintenanceinchinesepatientswithadvancedmetastaticsofttissuesarcoma